AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phenylalanine--tRNA ligase alpha subunit

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y285

UPID:

SYFA_HUMAN

Alternative names:

CML33; Phenylalanyl-tRNA synthetase alpha subunit

Alternative UPACC:

Q9Y285; B4E363; Q9NSD8; Q9Y4W8

Background:

The Phenylalanine--tRNA ligase alpha subunit, also known by its alternative names CML33 and Phenylalanyl-tRNA synthetase alpha subunit, plays a crucial role in protein synthesis. It is responsible for the ligation of phenylalanine to its corresponding tRNA, a fundamental process in the translation of genetic information into functional proteins.

Therapeutic significance:

Linked to Rajab interstitial lung disease with brain calcifications 2, a disorder characterized by lung disease, growth delay, and brain abnormalities, the Phenylalanine--tRNA ligase alpha subunit's study could lead to novel therapeutic approaches for this and potentially other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.